ReviewOncogene2000
Ets factors and regulation of the extracellular matrix.
Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 124 citations in OpenAlex.
- Enhanced diagnosis of extramural venous invasion in esophageal carcinoma: endothelial ETS-related gene, laminin and α-smooth muscle actin plus elastic staining.Virchows Archiv : an international journal of pathology · 2026Article
- MatriCom, a single-cell RNA-sequencing data mining tool to infer cell-extracellular matrix interactions.Journal of cell science · 2025Article
- GABPB1 plays a cancer-promoting role in non-small cell lung cancer.Discover oncology · 2024Article
- Dysregulation of murine long noncoding single-cell transcriptome in nonalcoholic steatohepatitis and liver fibrosis.RNA (New York, N.Y.) · 2023Article
- Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.JCI insight · 2022Article
- Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis.Experimental and therapeutic medicine · 2022Article
- The Matrisome Is Associated with Metabolic Reprograming in Stem-like Phenotypes of Gastric Cancer.Cancers · 2022Article
- Developmental Neuropathology and Neurodegeneration of Down Syndrome: Current Knowledge in Humans.Frontiers in cell and developmental biology · 2022Review
- Ets-2 deletion in myeloid cells attenuates IL-1α-mediated inflammatory disease caused by a Ptpn6 point mutation.Cellular & molecular immunology · 2021Article
- EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non‑small cell lung cancer cells.Oncology reports · 2021Observational
- High-Throughput Identification of MiR-145 Targets in Human Articular Chondrocytes.Life (Basel, Switzerland) · 2020Article
- ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.Molecular therapy. Nucleic acids · 2019Article
- Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.Blood advances · 2018Article
- BRD4 is a novel therapeutic target for liver fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- ETS1 induces human trophoblast differentiation.Endocrinology · 2015Article
- Transcriptional regulators of claudins in epithelial tight junctions.Mediators of inflammation · 2015Review
- Pea3 transcription factor family members Etv4 and Etv5 mediate retrograde signaling and axonal growth of DRG sensory neurons in response to NGF.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α.Diabetologia · 2013Article
- Understanding the role of ETS-mediated gene regulation in complex biological processes.Advances in cancer research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ets factors are critical mediators of extracellular matrix (ECM) remodelling. As the spectrum of Ets-regulated target genes widens, so does their role in various pathological and physiological processes. Regulation of matrix degrading proteases by Ets factors in tumor invasion and metastasis is well established. Emerging evidence suggests that they may also play a role in the pathology of autoimmune diseases. Newly characterized Ets target genes such as tenascin-C and collagen type I suggest their role in diseases characterized by aberrant collagen deposition (fibrosis). Ets function is also critical in bone and cartilage development. There is increasing knowledge of the complex regulatory mechanisms involved in transcription of Ets target genes. Ets factors may function as activators or as repressors via association with specific cofactors depending on the promoter context. Signaling pathways can modulate the activation status of Ets factors and their transcriptional partners. Precise understanding of the role of Ets factors in the complex cellular network governing the expression of ECM proteins and the enzymes that degrade them will be a focus of future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.